Title:
METHODS OF TREATING HEPATITIS C VIRUS INFECTION IN SUBJECTS WITH CIRRHOSIS
Document Type and Number:
WIPO Patent Application WO/2015/084741
Kind Code:
A3
Abstract:
Methods of treating hepatitis C virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of Compound 1.
Inventors:
DENNING JILL M (US)
MCHUTCHISON JOHN GEORGE (US)
SUBRAMANIAN G MANI (US)
SYMONDS WILLIAM THOMAS III (US)
MCHUTCHISON JOHN GEORGE (US)
SUBRAMANIAN G MANI (US)
SYMONDS WILLIAM THOMAS III (US)
Application Number:
PCT/US2014/067965
Publication Date:
July 30, 2015
Filing Date:
December 01, 2014
Export Citation:
Assignee:
GILEAD PHARMASSET LLC (US)
International Classes:
A61K31/4184; A61K45/06; A61K31/4188; A61K31/4709; A61K31/7056; A61K31/7068; A61P31/12; A61P31/14
Domestic Patent References:
| WO2014120981A1 | 2014-08-07 |
Other References:
IRA M. JACOBSON ET AL: "Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options", NEW ENGLAND JOURNAL OF MEDICINE, vol. 368, no. 20, 16 May 2013 (2013-05-16), pages 1867 - 1877, XP055174202, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1214854
LAWITZ ERIC ET AL: "Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study", HEPATOLOGY, vol. 58, no. 6, 26 November 2013 (2013-11-26), & 64TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVER-DISEASES; WASHINGTON, DC, USA; NOVEMBER 01 -05, 2013, pages 1380A, XP008175296
ERIC LAWITZ ET AL: "Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection", NEW ENGLAND JOURNAL OF MEDICINE, vol. 368, no. 20, 16 May 2013 (2013-05-16), pages 1878 - 1887, XP055174393, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1214853
LAWITZ E ET AL: "Once daily Sofosbuvir/Ledipasvir fixed dose combination with or without ribavirin resulted in > 95% sustained virologic response in patients with HCV genotype 1, including in patients with cirrhosis: the LONESTAR trial", HEPATHOLOGY, vol. 58, no. 4 suppl, 1 October 2013 (2013-10-01), pages 315A - 316A, XP002737696
CURE S ET AL: "Long-term outcomes of sofosbuvir for the treatment of chronic hepatitis C infected patients (abstract 1107)", HEPATHOLOGY, vol. 58, no. 4 SUPPL, 1 October 2013 (2013-10-01), pages 747A, XP007923038
LAWITZ ERIC ET AL: "Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study", HEPATOLOGY, vol. 58, no. 6, 26 November 2013 (2013-11-26), & 64TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVER-DISEASES; WASHINGTON, DC, USA; NOVEMBER 01 -05, 2013, pages 1380A, XP008175296
ERIC LAWITZ ET AL: "Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection", NEW ENGLAND JOURNAL OF MEDICINE, vol. 368, no. 20, 16 May 2013 (2013-05-16), pages 1878 - 1887, XP055174393, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1214853
LAWITZ E ET AL: "Once daily Sofosbuvir/Ledipasvir fixed dose combination with or without ribavirin resulted in > 95% sustained virologic response in patients with HCV genotype 1, including in patients with cirrhosis: the LONESTAR trial", HEPATHOLOGY, vol. 58, no. 4 suppl, 1 October 2013 (2013-10-01), pages 315A - 316A, XP002737696
CURE S ET AL: "Long-term outcomes of sofosbuvir for the treatment of chronic hepatitis C infected patients (abstract 1107)", HEPATHOLOGY, vol. 58, no. 4 SUPPL, 1 October 2013 (2013-10-01), pages 747A, XP007923038
Attorney, Agent or Firm:
ROZSNYAI, Lawrence F. et al. (Inc.333 Lakeside Driv, Foster City CA, US)
Download PDF:
Previous Patent: OPTIMIZED DEWATERING PROCESS
Next Patent: PASTA PROCESSING FOR LOW PROTEIN FLOUR AND DECREASED DRYING
Next Patent: PASTA PROCESSING FOR LOW PROTEIN FLOUR AND DECREASED DRYING